Ashland posts $742 million Q3 net loss on $706 million impairment; sales fall 15%
Ashland reported preliminary third-quarter fiscal 2025 sales of $463 million, down 15 percent from $544 million a year earlier, and a net loss of $742 million, or $(16.21) per diluted share, mainly due to a non-cash goodwill impairment charge of $706 million. The company also narrowed its full-year fiscal 2025 outlook to sales of $1.825 billion to $1.850 billion and Adjusted EBITDA of $400 million to $410 million, with current assumptions weighted toward the lower end. For shareholders, the large charge and weaker sales and Adjusted EBITDA are the key takeaways, and the results remain preliminary until the Form 10-Q is filed.
Key points
- Q3 sales of $463 million, down 15 percent; Portfolio Optimization reduced sales by about $53 million, or 10 percent
- Net loss of $742 million, or $(16.21) per diluted share, including the $706 million goodwill impairment charge
- Adjusted EBITDA of $113 million, down 19 percent from $139 million a year earlier
- Full-year fiscal 2025 outlook narrowed to sales of $1.825 billion to $1.850 billion and Adjusted EBITDA of $400 million to $410 million
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.